Advertisement
BSX vs NTRA
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Boston Scientific (BSX) is a large, diversified medical-device leader, while Natera (NTRA) is a faster-growing precision-diagnostics and genetic-testing company.
- BSX delivered strong double-digit revenue growth but saw its shares sell off recently on segment-specific concerns; NTRA has posted accelerating revenue and improving gross margins.
- The two names represent contrasting risk profiles: BSX offers scale and diversification, while NTRA offers higher growth with a still-narrowing profitability path.
- Recent market momentum has favored NTRA, whose relative performance and trend consistency have been stronger over recent months.
- Sector exposure differs sharply, with BSX tied to cardiovascular and surgical devices and NTRA tied to oncology and reproductive health testing.
Introduction
Investors evaluating healthcare stocks often weigh stability against growth. This stock comparison examines two very different businesses operating under the broad healthcare umbrella: BSX, Boston Scientific Corporation, a diversified medical-device manufacturer, and NTRA, Natera, a precision-diagnostics company built around cell-free DNA (cfDNA) testing. The comparison is relevant for traders seeking relative performance signals as well as longer-term investors assessing market positioning, growth drivers, and risk. By reviewing recent performance, momentum, and structural trade-offs, readers can better understand how these two names stack up in the current environment.
BSX Overview and Recent Performance
BSX (Boston Scientific Corporation) is a global medical-technology company whose products span cardiovascular devices, endoscopy, urology, and neuromodulation. The company reported full-year revenue above $20 billion in its most recent fiscal year, up roughly 20% year over year on a reported basis, supported by franchises such as WATCHMAN (a left atrial appendage closure device) and its pulsed field ablation (PFA) portfolio for atrial fibrillation.
Despite strong top-line results, BSX shares have faced notable selling pressure in recent weeks. Sentiment weakened around concerns including sequential softness in U.S. electrophysiology (EP) sales, a modest miss in U.S. WATCHMAN, supply-chain disruptions in urology, and an endoscopy product removal. The company has also pursued merger-and-acquisition (M&A) activity, announcing agreements for strategic acquisitions to expand adjacent markets. Management has guided for organic revenue growth in the low double digits for the current year, but near-term relative performance has lagged the broader market.
NTRA Overview and Recent Performance
NTRA (Natera, Inc.) is a diagnostics company focused on molecular and genetic testing across oncology, women's health, and organ health. Its growth has been driven primarily by Signatera, a minimal residual disease (MRD) test used to monitor cancer patients. In its most recent fiscal year, Natera's revenue rose roughly 35% to about $2.3 billion, while fourth-quarter revenue climbed approximately 40% year over year.
Recent market activity has been constructive for NTRA, with shares generally trending higher as clinical MRD test volumes accelerated by more than 50% year over year and gross margins expanded toward the high-60s percentage range. The company continues to report a GAAP net loss, but losses have narrowed and it has generated positive operating cash flow, improving its financial footing. Strong clinical data readouts and expanding Medicare coverage momentum have reinforced investor confidence, supporting more favorable relative performance in recent weeks.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page offers a curated selection of AI-driven trading bots. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and watchlists. Because not every bot is equally suited to shifting market conditions, only the strongest and most relevant performers are featured in the Trending AI Robots section. These bots apply quantitative, pattern-recognition approaches to help identify trading opportunities across names like those discussed in this stock comparison. To explore the current lineup and see which strategies are resonating with today's market, visit the Trending AI Robots page.
Head-to-Head Comparison
The core contrast between these two companies is business model and growth stage. BSX is a mature, diversified device maker generating substantial profitability and cash flow, with growth tied to product innovation and M&A. NTRA is a diagnostics platform earlier in its profitability curve, where revenue growth and gross-margin expansion matter more than current earnings.
Growth drivers also differ. BSX leans on cardiovascular devices and interventional procedures, while NTRA depends on adoption of molecular testing in oncology and reproductive health. Risk factors vary accordingly: BSX faces competitive pressure in EP and supply-chain execution risk, whereas NTRA faces reimbursement and regulatory sensitivity, plus a competitive diagnostics landscape. On recent momentum, NTRA has shown stronger relative performance and a more consistent uptrend, while BSX has experienced a pullback despite solid fundamentals. Market sentiment, as reflected in recent price action, has favored NTRA's growth narrative over BSX's scale-and-diversification story.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and catalyst positioning, Tickeron's AI would likely favor NTRA in the current environment. The stock's accelerating revenue growth, improving gross margins, and constructive price trend present a more favorable near-term setup than BSX's recent pullback, which reflects segment-specific headwinds. That said, BSX's diversification and cash-flow strength offer a more stable foundation, meaning the two names may appeal to different risk profiles. Any AI-driven assessment remains probabilistic rather than definitive, grounded in current data and subject to change as market conditions evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a StrongBuy and NTRA is a Hold.
Momentum Indicator for BSX turns positive, indicating new upward trend
BSX saw its Momentum Indicator move above the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 56 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 15 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on November 09, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 25 of 46 cases over the following month. The odds of a continued upward trend are 54%.
BSX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 201 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NTRA in downward trend: 10-day moving average moved below 50-day moving average on November 10, 2026
The 10-day moving average for NTRA crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 69 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 34 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
NTRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for NTRA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NTRA's RSI Indicator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.585) is normal, around the industry mean (67.298). NTRA's P/E Ratio (-230.126) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 26 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. NTRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BSX | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 97 | 26 | |
SMR RATING 1..100 | 55 | 94 | |
PRICE GROWTH RATING 1..100 | 62 | 46 | |
P/E GROWTH RATING 1..100 | 95 | 69 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for BSX (66) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than BSX’s over the last 12 months.
NTRA's Profit vs Risk Rating (26) in the Biotechnology industry is significantly better than the same rating for BSX (97) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than BSX’s over the last 12 months.
BSX's SMR Rating (55) in the Medical Specialties industry is somewhat better than the same rating for NTRA (94) in the Biotechnology industry. This means that BSX’s stock grew somewhat faster than NTRA’s over the last 12 months.
NTRA's Price Growth Rating (46) in the Biotechnology industry is in the same range as BSX (62) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
NTRA's P/E Growth Rating (69) in the Biotechnology industry is in the same range as BSX (95) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
| BSX | NTRA | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 60% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 49% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 54% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 55% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 78% |
| Advances ODDS (%) | 2 days ago 60% | 9 days ago 79% |
| Declines ODDS (%) | 7 days ago 54% | 7 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 5 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s).
- BSX’s TA Score: 5 bullish, 4 bearish.
- NTRA’s TA Score: 4 bullish, 6 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а -1.51% price change this week, while NTRA (@Medical Specialties) price change was -18.21% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +5.70%. For the same industry, the average monthly price growth was -2.49%, and the average quarterly price growth was -1.73%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.30%. For the same industry, the average monthly price growth was -5.99%, and the average quarterly price growth was +36.57%.
Reported Earning Dates
BSX is expected to report earnings on Feb 03, 2027.
NTRA is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Medical/Nursing Services (+5.70% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-0.30% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +0.96% | ||
| ISRG - BSX | 71% Closely correlated | -0.11% | ||
| MMSI - BSX | 56% Loosely correlated | +0.30% | ||
| ALC - BSX | 49% Loosely correlated | -2.16% | ||
| MDT - BSX | 48% Loosely correlated | +0.02% | ||
| NTRA - BSX | 45% Loosely correlated | +2.51% | ||
More | ||||